“Three years back, when we started, we had a significant debt. But, today we are a debt-free company and we also have significant investmen...

The dollar advanced against most major currencies overnight, recouping recent losses, as traders shunned riskier currencies over concerns a...

Appetite for Japanese stocks is getting stronger as investors see them as a bargain," said Chihiro Ohta, assistant general manager, investm...

Investors globally are on edge as surging borrowing costs stoke fears of widespread recession, with most of the world's major central banks...

The Nikkei share average ended up 0.44% at 27,803, topping the six-week high reached the previous day. The broader Topix added 0.21% to 1,9...

"Recent losses in domestic equities were driven by concerns about economic slowdown due to the Federal Reserve's tightening monetary policy...

The pills have to be started as soon as possible, within five days of the start of symptoms.

The Nikkei share average ended 1.93% higher at 26,843.49 - the biggest jump since March 22 - and marked a sharp rebound from its near four-...

Vaccine developers only bringing shots to the testing phase now are finding it an uphill battle, with the developed world so highly vaccina...

The Nikkei share average ended 0.34 per cent higher at 28,958.56, while the broader Topix ticked down 0.02 per cent to 1,956.73.

A new drug, Cabotegravir, has been proven to be 90 per cent more effective than the daily pill known as PrEP against AIDS. Cabotegravir is ...

The new branded product portfolio has a strong fit with Lupin’s Kyowa business, as it adds depth and reach to its current CNS (central nerv...

The acquisition will result in a wider offering for Lupin in Japanese market where its sales last fiscal stood at Rs 1,364 crore.

AstraZeneca settleS a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in all importa...

In December last year, Shionogi's request for a preliminary injunction had been granted and had blocked Lupin from further sales of the pro...

The US court, however, denied the motion of Shionogi for recall of Lupin's already distributed generic Fortamet during the two weeks of at-...

Drug maker Ranbaxy Laboratories today said it has received approval from the US drug regulator for manufacturing and marketing the generic ...